Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 30.4 USD -1.17% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Agios Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one AGIO stock under the Base Case scenario is 36.49 USD. Compared to the current market price of 30.4 USD, Agios Pharmaceuticals Inc is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AGIO Relative Value
Base Case
36.49 USD
Undervaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

47.6
P/S
P/S
Price to Sales
47.6
vs History
53
vs Industry
20
Median 3Y
75
Median 5Y
53.3
Industry
7.2
Forward
31.6
More Details
2.6
P/E
P/E
Price to Earnings
2.6
vs History
9
vs Industry
12
Median 3Y
-4.5
Median 5Y
-5.1
Industry
21.4
Forward
-4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.5
Industry
20.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.4
Industry
24.5
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
92
vs Industry
57
Median 3Y
1.5
Median 5Y
1.6
Industry
2.4
More Details
23.1
EV/S
EV/S
Enterprise Value to Sales
23.1
vs History
52
vs Industry
24
Median 3Y
43.1
Median 5Y
27
Industry
7.4
Forward
15.4
More Details
26.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
26.1
vs History
52
vs Industry
21
Median 3Y
49.3
Median 5Y
30.5
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-2.7
Industry
4.1
Forward
-1.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.7
Industry
3.8
Forward
-1.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3
Industry
5.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3
Industry
3.3
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
92
vs Industry
55
Median 3Y
1.9
Median 5Y
3.1
Industry
4.4
More Details

Multiples Across Competitors

AGIO Competitors Multiples
Agios Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
1.7B USD 47.6 2.6 -2 -2
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 908 785.7 -175 422 -213 018.2 -210 587.4
US
Abbvie Inc
NYSE:ABBV
355.3B USD 6.3 83.8 16.5 24.9
US
Amgen Inc
NASDAQ:AMGN
164.1B USD 4.9 40.1 16.2 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
136.2B USD 4.7 283.6 11.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -240 26.3 27.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 908.7 -487.1 -530.4 -516.3
AU
CSL Ltd
ASX:CSL
122.3B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.2B USD 4.9 15.9 10.3 11.5
US
Seagen Inc
F:SGT
39.3B EUR 18.4 -56.4 -60.6 -54.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.8B USD 15.5 -125.1 -275.7 -187.3
P/S Multiple
Revenue Growth P/S to Growth
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Average P/S: 3 355 528.5
47.6
121%
0.4
FR
Pharnext SCA
OTC:PNEXF
36 908 785.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 908.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.4
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.5
28%
0.6
P/E Multiple
Earnings Growth PEG
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Average P/E: 75.7
2.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -175 422 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.8
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
283.6
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -487.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -125.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Average EV/EBITDA: 16.3
Negative Multiple: -2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 018.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.1
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -275.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Average EV/EBIT: 21.4
Negative Multiple: -2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 587.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -187.3 N/A N/A

See Also

Summary
AGIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGIO stock valuation using valuation multiples.
Wall Street Estimates
AGIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.